about
Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsyFenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, exerts anticonvulsive properties[Neonatal arterial ischemic stroke: Review of the current guidelines].MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations.[Quality of health information about epilepsy on the Internet: Evaluation of French websites].Outcome of status epilepticus. What do we learn from animal data?Age-dependent effects of topiramate on the acquisition and the retention of rapid kindling.Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain.Comparison of Brain Maturation among Species: An Example in Translational Research Suggesting the Possible Use of Bumetanide in NewbornThe classification of chronic daily headache in French children and adolescents: a comparison between the second edition of the International Classification of Headache Disorders and Silberstein-Lipton criteria.A microRNA-328 binding site in PAX6 is associated with centrotemporal spikes of rolandic epilepsy.Finding a better drug for epilepsy: antiepileptogenesis targets.Treatment of juvenile myoclonic epilepsy.Fatty acid oxidation and epilepsy.Hemiconvulsion-hemiplegia-epilepsy syndrome: current understandings.Should we routinely use modified Atkins diet instead of regular ketogenic diet to treat children with epilepsy?Novel animal models of pediatric epilepsy.Inflammation and epilepsy in the developing brain: clinical and experimental evidence.Prospective clinical trials to investigate clinical and molecular biomarkers.Current understanding and neurobiology of epileptic encephalopathies.Non-pharmacological medical treatment in pediatric epilepsies.Ketogenic diet guidelines for infants with refractory epilepsy.Advancing pharmacologic treatment options for pharmacologic treatment options for children with epilepsy.Different response to antiepileptic drugs according to the type of epileptic events in a neonatal ischemia-reperfusion model.Oral administration of docosahexaenoic acid/eicosapentaeinoic acids is not anticonvulsant in rats: implications for translational research.Epilepsy diagnostic and treatment needs identified with a collaborative database involving tertiary centers in France.Ketogenic diet exhibits anti-inflammatory properties.Perceptions of fever and fever management practices in parents of children with Dravet syndrome.Inflammation in rat pups subjected to short hyperthermic seizures enhances brain long-term excitability.[Febrile seizures: current understanding of pathophysiological mechanisms].Autosomal-Recessive Mutations in AP3B2, Adaptor-Related Protein Complex 3 Beta 2 Subunit, Cause an Early-Onset Epileptic Encephalopathy with Optic AtrophyWWOX-related encephalopathies: delineation of the phenotypical spectrum and emerging genotype-phenotype correlation.A case of Lennox-Gastaut syndrome in a patient with FOXG1-related disorder.Acute neuroprotection to pilocarpine-induced seizures is not sustained after traumatic brain injury in the developing rat.Inflammation enhances epileptogenesis in the developing rat brainInflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA.Hearing hallucinations in a 12-year-old child: psychotic disorders or temporal epilepsy?Aggravation of absence seizure related to levetiracetam.Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling.Ketogenic diet for infantile spasms refractory to first-line treatments: an open prospective study.
P50
Q28267579-F8AF7BD3-7CD6-4D85-982C-225A2C3995D8Q28302788-20252EA0-52FC-4F14-8CBD-B4D48A5F1BD5Q31150983-9A81FD25-B0FE-4632-A166-E5AF4E5F578FQ33766816-3DC324F6-93A1-4D5B-9CE8-F5582208518BQ34306221-9105A59B-7FCA-48E3-A2DC-F3170D7558DEQ35342111-6743817B-468D-422F-8002-28CD7A8454F4Q36647742-76244C70-048F-4BC4-A9EA-894100163562Q36690609-20BDBCA0-6BC4-4062-BFE4-E04C0FECC2BAQ36764504-E7532513-C55B-4CEF-8FDE-E64ED0F5C9C2Q36836824-CBC1C8C9-4C87-4D49-9CBF-DBEAFBD0DD6CQ37062120-872BCA24-B172-4102-A9E7-8B99E56F6EF2Q37232240-716B159B-69DB-40A8-8440-48FAE89DA2EDQ37236519-7178FA04-227D-4BA2-9369-05774F9E62E6Q37920317-0E679BF3-D0B3-4338-B004-4E3DBF0B6796Q37984928-C7B8BA74-C383-4756-97D6-CB735CA39630Q37994455-61098EDE-2067-4D88-ABB0-CFAA28CD7FDFQ37998957-62E066AA-F168-4F49-AECB-DB18EE09791EQ38325826-F1AAEEBA-E657-45A8-9CB1-758E7160BAD9Q38694561-853E570F-7FE2-49BC-AE56-93B27D0B7644Q38780751-7EA6CC52-5494-447C-BB39-DD4BCB54C695Q38781056-D2417D48-9CDA-495F-A8EE-11DFCF8E7666Q38836591-F7C63C84-04C3-4368-87F5-0F0486991F92Q38850130-FBAB78EB-5E84-4A68-9492-4DC68A1D2EC6Q39044899-D56A176B-6F4C-4EBE-AB93-BB6CD77D6A43Q39715633-0F51EB33-0138-4199-83B6-B9CC698B6FF8Q39870180-A37AE7D1-5519-4BDA-93F8-E5563429EB5DQ40154513-06E53D9E-1299-49E5-BA78-938D35038E92Q40320538-F0297FC1-2FEA-4B47-82B3-C19D1801C7C1Q40386767-5C2E3ADB-6827-4748-B78C-938B0795D210Q40394107-112B578B-BA92-4498-8085-AA0F87BDA5CCQ41921675-9D4EFE46-F1D9-41DA-9061-8E439998FBCBQ41929086-92186768-DAE0-4169-938D-A4EB373ADAA0Q41929340-E21BF720-1706-4EEF-B919-D0E0EE310953Q41930078-68481A33-D933-414B-8002-B7D58540877CQ42018190-48DF7C88-92F4-44E7-9349-E7A007C9F2B3Q42195288-AD89AA3F-B8C1-4B31-82EF-98544BD2AFE0Q42425447-1B9DA865-EB32-441E-8B28-765EA3FEF5CCQ42605329-F44D0AA0-648A-4932-91D1-63101D4BE185Q42654751-6ED55378-4FD7-488D-A9E1-093BE11722C8Q42684782-9E21EA7B-F2BE-40C0-B3E5-40648787CDFF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stéphane Auvin
@ast
Stéphane Auvin
@en
Stéphane Auvin
@es
Stéphane Auvin
@nl
Stéphane Auvin
@sl
type
label
Stéphane Auvin
@ast
Stéphane Auvin
@en
Stéphane Auvin
@es
Stéphane Auvin
@nl
Stéphane Auvin
@sl
prefLabel
Stéphane Auvin
@ast
Stéphane Auvin
@en
Stéphane Auvin
@es
Stéphane Auvin
@nl
Stéphane Auvin
@sl
P106
P1153
15135263800
P21
P31
P496
0000-0003-3874-9749